UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~June~~December 2718, 2007

ASPREVA PHARMACEUTICALS CORPORATION

(Exact Name of Registrant as Specified in Charter)

British Columbia, Canada

(State or Other Jurisdiction of Incorporation)


000-51169	98-0435540
(Commission File Number)	(IRS Employer Identification No.)

1203-4464 Markham Street

Victoria, British Columbia, Canada V8Z 7X8

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: (250) 744-2488

Not Applicable ~~(Former name or former address, if changed since last report)~~

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~ITEM~~Item 8.01. ~~OTHER~~ Other ~~EVENTS~~Events.

On ~~June~~December 2718, 2007, ~~Aspreva~~the ~~Pharmaceuticals~~British ~~Corporation~~Columbia Supreme Court issued a ~~press~~final ~~release~~order ~~announcing~~approving ~~its~~a ~~preliminary~~statutory ~~results~~plan ~~for~~of arrangement under the ~~phase~~Business ~~III~~Corporations Act ~~study~~(British ~~evaluating~~Columbia), ~~CellCept~~pursuant to which Galenica AG, through Galenica inCanada ~~lupus nephritis~~Ltd., ~~The~~a ~~press~~wholly-owned ~~release~~Canadian issubsidiary, ~~attached~~will ~~hereto~~acquire asall ~~Exhibit 99.1~~outstanding ~~and~~common ~~is incorporated~~shares ~~herein~~of byAspreva ~~reference~~Pharmaceuticals at a price of US$26.00 per share in cash.

~~ITEM~~The 9acquisition is expected to close on January 3, 2008 subject to the satisfaction or waiver of the conditions specified in the Combination Agreement among Galenica AG, Galenica Canada Ltd.01 and Aspreva Pharmaceuticals Corporation, dated October 17, 2007. ~~FINANCIAL~~ ~~STATEMENTS~~The ~~AND~~Combination ~~EXHIBITS~~Agreement is filed as Exhibit 2.1 to our Current Report on Form 8-K (File No. 000-51169) dated October 17, 2007, and filed with the U.S. Securities and Exchange Commission on October 18, 2007.

A copy of the press release, dated December 18, 2007, entitled “Aspreva Receives Final Court Approval for Acquisition by Galenica” is attached hereto as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

Exhibit No.		Description
99.1		Press ~~Release~~release, dated December 18, 2007, entitled “Aspreva ~~and~~Receives ~~Roche~~Final ~~Announce~~Court ~~Preliminary~~Approval ~~Results~~ for ~~Phase~~Acquisition ~~III~~by ~~Study Evaluating CellCept in Lupus Nephritis,~~Galenica” ~~dated June 27, 2007~~.

~~Signatures~~SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ASPREVA PHARMACEUTICALS CORPORATION
Dated: June 27, 2007
Dated: December 18, 2007
	By:	/s/ Bruce G. Cousins
		Bruce G. Cousins
		Executive Vice President & Chief Financial Officer

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press ~~Release~~release, dated December 18, 2007, entitled “Aspreva ~~and~~Receives ~~Roche~~Final ~~Announce~~Court ~~Preliminary~~Approval ~~Results~~ for ~~Phase~~Acquisition ~~III~~by ~~Study Evaluating CellCept in Lupus Nephritis,~~Galenica” ~~dated June 27, 2007~~.

Filing Compare · Aspreva Pharmaceuticals CORP